GlaxoSmithKline plc and Theravance, Inc. today announced that the US Food and Drug Administration has approved BREO® ELLIPTA® for the once-daily treatment of asthma in patients aged 18 years and older ...

Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...

Recently, the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application for Trelegy Ellipta for the maintenance treatment of asthma in patients ages 18 years and older.

Adherium, a New Zealand-based maker of connected respiratory medical devices, has received the US Food and Drug Administration's 510(k) clearance for connecting its digital monitoring platform with ...

Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...

Keep in mind that when you open the cover of the inhaler, the device makes one dose of the drug available to inhale. If you open and close Anoro Ellipta’s cover without taking the dose, you will lose ...

If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...